Venture

We have developed and patented a novel preservation solution to be used as a clinical treatment for ischemia-reperfusion injury in organ transplantation, particularly intestinal transplantation.

Team:
Ming Zhang, MD, PhD. – President, CEO
Xiang Li
Andrew Hitchings